Revolution Medicines

Yahoo Finance • yesterday

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointm... Full story

Yahoo Finance • 5 days ago

These 2 Stocks Could Be Prime Takeover Targets, According to Analysts

What began as a cautious ride earlier in the year has swelled into a full-blown bull market. The S&P 500 has climbed 14% in 2025, while the NASDAQ, lifted by the AI boom, has surged 17%. Elevate Your Investing Strategy: Take advantage of... Full story

Yahoo Finance • 19 days ago

Stocks making the biggest moves midday: Delta Air Lines, Revolution Medicines, Centene & more

Check out the companies making the biggest moves midday: Revolution Medicines — The biotech stock rallied 13% on the release of positive trial data for daraxonrasib, a drug aimed at treating pancreatic cancer. The company plans to begin a... Full story

Yahoo Finance • 19 days ago

Stocks Climb as US Labor Market Weakness Bolsters Fed Rate Cut Expectations

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.22%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 20 days ago

Revolution Medicines rises on daraxonrasib data that supports phase 3 program

[Human Pancreatic Cancer] wildpixel * Revolution Medicines (NASDAQ:RVMD [https://seekingalpha.com/symbol/RVMD]) said that new clinical results from several phase 1 clinical trials support moving daraxonrasib into a phase 3 program for f... Full story

Yahoo Finance • 20 days ago

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinical results for daraxonrasib monotherap... Full story

Yahoo Finance • last month

Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the most promising future stocks according to Wall Street analysts. On August 18, Piper Sandler initiated coverage of Revolution Medicines, Inc. (NASDAQ:RVMD) with an Overweight rating and... Full story

Yahoo Finance • last month

Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now. Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical collaboration with Revolution Medicines.Summit... Full story

Yahoo Finance • last month

Revolution Medicines' SWOT analysis: promising cancer drug stock faces pivotal year

Revolution Medicines, Inc. (NASDAQ:RVMD) is a biotechnology company at the forefront of developing novel therapies for cancer, with a particular focus on pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). With... Full story

Yahoo Finance • 2 months ago

Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical progress

Revolution Medicines Inc. (NASDAQ:RVMD), a biotechnology company focused on developing novel therapies for cancer treatment, has been making significant strides in its clinical pipeline, particularly in the areas of pancreatic ductal adeno... Full story

Yahoo Finance • 2 months ago

Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy

Earnings Call Insights: Revolution Medicines (RVMD) Q2 2025 MANAGEMENT VIEW * CEO Mark A. Goldsmith outlined progress across Revolution Medicines’ RAS(ON) inhibitor pipeline, highlighting “a compelling pipeline of 3 distinguished clini... Full story

Yahoo Finance • 2 months ago

Revolution Medicines Inc (NASDAQ:RVMD) Reports Q2 2025 Earnings Miss, Shares Drop 4.5% After-Hours

Revolution Medicines Inc (NASDAQ:RVMD [https://www.chartmill.com/stock/quote/RVMD]) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The clinical-stage oncology... Full story

Yahoo Finance • 2 months ago

Revolution Medicines GAAP EPS of -$1.31 misses by $0.29

* Revolution Medicines press release [https://seekingalpha.com/pr/20191831-revolution-medicines-reports-second-quarter-2025-financial-results-and-update-on-corporate] (NASDAQ:RVMD [https://seekingalpha.com/symbol/RVMD]): Q2 GAAP EPS of -... Full story

Yahoo Finance • 2 months ago

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RA... Full story

Yahoo Finance • 2 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will... Full story

Yahoo Finance • 2 months ago

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments

Neil Gallagher M.D., Ph.D., former AbbVie Chief Medical Officer and President of R&D at Syndax, brings considerable experience in oncology drug development Anthony Mancini, currently Global Chief Commercial Officer at Revolution Medicines,... Full story

Yahoo Finance • 2 months ago

Castle Biosciences, Revolution Medicines get FDA breakthrough statuses

[US Food and Drug Administration (FDA)] Castle Biosciences (NASDAQ:CSTL [https://seekingalpha.com/symbol/CSTL]) said on Wednesday that it has received breakthrough device designation from the U.S. Food and Drug Administration for its Deci... Full story

Yahoo Finance • 3 months ago

Revolution Medicines Fair Value call captures 40% downside in biotech stock

Investing.com’s Fair Value model demonstrated its predictive power by accurately identifying significant overvaluation in Revolution Medicines (NASDAQ:RVMD) shares last November. The model’s analysis, which combines multiple valuation meth... Full story

Yahoo Finance • 3 months ago

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidatesIambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone paymen... Full story

Yahoo Finance • 3 months ago

Revolution Medicines' SWOT analysis: stock's potential in cancer therapies

Revolution Medicines, Inc. (NASDAQ:RVMD) is making waves in the biotechnology sector with its innovative approach to cancer treatment, particularly in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). With a m... Full story